![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
https://www.globenewswire.com/news-release/2024/05/06/2875759/37414/en/Panbela-Announces-Issuance-of-New-Patent-in-the-US-and-Canada-Patent-is-for-Claims-of-a-Fixed-Dose-Combination-of-Eflornithine-and-Sulindac.html
https://www.globenewswire.com/news-release/2024/04/30/2872189/37414/en/Acceptance-of-Eflornithine-DFMO-Abstract-for-Oral-Presentation-at-Digestive-Disease-Week.html
https://www.prnewswire.com/news-releases/norgine-bv-submits-marketing-authorisation-application-via-project-orbis-for-eflornithine-difluoromethylornithine-dfmo-in-high-risk-neuroblastoma-302116815.html
https://www.globenewswire.com//news-release/2023/12/18/2797829/37414/en/Panbela-Therapeutics-Announces-US-WorldMeds-NDA-Approval-for-Eflornithine-DFMO-in-Pediatric-Neuroblastoma.html
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-eflornithine-adult-and-pediatric-patients-high-risk-neuroblastoma?utm_medium=email&utm_source=govdelivery
https://www.globenewswire.com/news-release/2023/06/01/2680311/37414/en/Panbela-Announces-Poster-Presentation-at-Immunology-of-Diabetes-Society-Meeting-Evaluating-the-Potential-of-CPP-1X-Eflornithine-in-Recent-Onset-Type-1-Diabetes.html
https://www.globenewswire.com/news-release/2023/01/10/2586093/36946/en/Orbus-Therapeutics-Enters-Exclusive-License-Agreement-for-Intellectual-Property-Related-to-Treatment-of-Rare-Pediatric-Syndrome-with-Eflornithine.html
https://www.globenewswire.com/news-release/2022/01/19/2369409/36946/en/Orbus-Therapeutics-Phase-3-Eflornithine-STELLAR-Study-Reaches-Full-Patient-Enrollment.html
https://www.globenewswire.com/news-release/2020/12/23/2150089/0/en/Orbus-Therapeutics-Receives-U-S-Patent-for-Eflornithine-Formulations.html#:~:text=PALO%20ALTO%2C%20Calif.%2C%20Dec,entitled%20%E2%80%9CFormulations%20for%20Administration%20of
https://www.globenewswire.com/news-release/2020/12/23/2150089/0/en/Orbus-Therapeutics-Receives-U-S-Patent-for-Eflornithine-Formulations.html#:~:text=PALO%20ALTO%2C%20Calif.%2C%20Dec,entitled%20%E2%80%9CFormulations%20for%20Administration%20of
https://www.clinicaltrialsarena.com/news/stellar-clinical-trial-eflornithine/
http://www.biospace.com/News/bay-area-startup-orbus-nabs-32-5-million-series-a/388610/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews